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A R T I C L E  I N F O A B S T R A C T
Introduction: In Australia, 18% of the population, experience or are diagnosed with some
form of joints diseases (IJD) such as arthritis. The average cost of arthritis treatment per
person per year is reported as Au$6200; 61% of arthritis costs are covered by the
individuals themselves.  Glucosamine is a complementary or alternative medicine used in
the treatment of Inflammatory Joint Disease (IJD).
Aim: The aim of this study was to explore consumers’ perception of the efficacy and
tolerance of glucosamine preparations in IJD.
Method: A 20-question survey was administered to members of the public to capture their
experience of the efficacy, the side-effects of glucosamine and to investigate if it was
prescribed or self-selected.  Also, which glucosamine salt was used, for how long it was
used and at what dose?
Results: From 87 participants, 91.9% stated that glucosamine reduced their pain and
91.7% stated that it improved their joint movement. In 46.5% participants pain reduced by
3-4 points and in 51.7% joints movement improved by 1-2 points. Glucosamine was used
by 60% for 6 months or more where improvement in pain and joint function by at least 1-
point was reported. Six participants reported glucosamine was not effective. There were no
reports of glucosamine intolerance. Five participants diagnosed with rheumatoid arthritis;
reported improvement in pain and joint movement by up to 2-points after taking daily
1500mg of Glucosamine Sulphate for over 6 months.
Discussion: This study provided insight on the possible benefits of glucosamine in
relieving pain and joints function associated with arthritis. Most studies reviewed that
reported effectiveness of glucosamine used glucosamine sulphate whilst those deemed
glucosamine ineffective had used the hydrochloride formulation. No research has been
conducted on the antioxidant activity of glucosamine in all IJD.
Conclusion: Five out of 87 participants had rheumatoid arthritis reported they found it was
effective. It is therefore recommended that further research be conducted to measure the
efficacy of glucosamine in treatment of different types of IJD and examining its antioxidant
property.
INTRODUCTION
In Australia, it is reported that 18% of the population
experience joint diseases (JD); approximately 3.85 million
people [1].  A public opinion poll (2008) [2] showed that
Australians were more worried about developing arthritis than
any other disease. The average cost of arthritis treatment per
person is Au$6200 a year, and 61% of arthritis costs are borne
by the individual patients themselves.
Glucosamine is not a prescription medicine in Australia, but a
complementary medicine, self-selected for the treatment of
osteoarthritis (OA) [3]. There is supporting evidence for its
effectiveness in treating OA of the knees but its effectiveness
in inflammatory joint diseases (IJD) such as Rheumatoid
Arthritis (RA) is lacking [4]. Recent in vitro research has
shown strong antioxidant activity of glucosamine [5, 6, 7, 8].
This paper presents arthritis and IJD patient experience of the
efficacy and tolerability of glucosamine in both OA and RA.
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Background
Rheumatoid Arthritis
RA is a systemic auto-immune inflammatory process
manifesting with joint swelling and tenderness [9]. The
inflammation is responsible for stimulating destructive
mechanisms in the joint, leading to functional decline and
disability [10]. The rheumatoid joint contains numerous cell
types that are involved [9, 10, 11].
IL-1 and tumour necrosis factor alpha (TNF-α) share many
pro-inflammatory actions in RA; and the rheumatoid joint also
contains other pro-inflammatory cytokines. Under normal
physiological conditions, the actions of pro-inflammatory
cytokines are balanced by anti-inflammatory cytokines. In the
rheumatoid joint, the balance swings in favour of the pro-
inflammatory cytokines [12].
Nitric oxide (NO) is produced through constitutive and
inducible pathways responsible for its pathogenic roles. NO
combines with reactive oxygen species (ROS) to produce
peroxynitrite (ONOO–), which promotes chondrocyte
apoptosis [13, 14, 15].
Osteoarthritis
OA is the most prevalent of IJDs. It differs from RA in its
aetiology; OA aetiology varies among individuals, with
possible roles for systemic factors, such as genetics and
obesity, as well as for local biomechanical factors, such as
muscle weakness, joint laxity, traumatic injury and stress. OA
is particularly frequent in the large, weight-bearing joints of
the lower limbs [16, 17].
As in RA, the inflammation of OA involves cytokines such as
IL-1, TNF-α, IL-6, IL-8, and NO, acting on chondrocytes to
cause a catabolic cascade where proteases break down proteins
in cartilage leading to inflammation.  This creates a positive
amplification loop leading to further protease production and
further cartilage degradation [18, 19, 20]. PGE 2 and NO play
important roles in cartilage catabolism in OA.
The role of Reactive Oxygen Species and Oxidative Stress in
Pathogenesis of Inflammatory Joint Disease
ROS are normal by-products of cellular metabolism, but in
disease states, overproduction occurs [21]. Amongst ROS, O2−
plays a pivotal role in inflammation, particularly in patients
with IJD [22]. The enzyme superoxide dismutase (SOD)
neutralises O2− by transforming it into H2O2, thereby
preventing the formation of highly aggressive compounds such
as ONOO− and HO– [23].
In IJD, pro-inflammatory cytokines and prostaglandins are
released, together with ROS [24] and NO [25]. These are
associated with low SOD concentrations in joint fluid [23].
Studies of nitrotyrosine residues in synovial tissues from
patients with RA [26] or exposure of chondrocytes to synthetic
ONOO– in vitro [27] established that the combination of O2–
and NO causes cartilage damage. Further evidence comes from
a study where intra-articular injections of native SOD (bovine
orgotein) produced greater improvements than intra-articular
aspirin in RA [28].
Oxidative Stress in Rheumatoid Arthritis
Although the causes of RA are unknown, involvement of ROS
is clear. In vitro, ONOO– formation is associated with
decreased production of type 2 collagen and aggrecan, and
with a diminished chondrocyte response to the growth factor
IGF-1. In addition, ONOO– increases the expression of MMP-
3 and MMP-13 and decreases the production and activity of
the tissue inhibitors of MMPs [24, 29]. Together, these
changes increase matrix breakdown.
TNF-α overproduction is thought the main contributor to
increased ROS release in RA. TNF-α cause cell damage and
inhibits SOD, decreasing enzyme activity neutralising O2− [30,
31].
Oxidative Stress in Osteoarthritis
IL-1-Beta (IL-1β) is one of the most active factors involved in
OA [32]. It diminishes expression of type-2 collagen and
aggrecan, and increases expression of MMPs-1 and 3. IL-1β
stimulates NO production, leading to the formation of ONOO–,
which targets guanine repeats in DNA telomeres, explaining
the link between oxidative stress and telomere erosion [33].
Aging of cartilage and chondrocytes may be central to the
pathogenesis and progression of OA.  Nitrotyrosine, formed
when tyrosine is oxidised in the presence of NO, can serve as a
measure of oxidative damage in vivo. Its presence in cartilage
was associated with older age and with OA, suggesting a role
of oxidative stress in cartilage aging and degeneration [34].
Pharmacological Treatment of Rheumatoid Arthritis
A combination of therapies is recommended in the treatment
of RA [4, 35, 36]:
 Rapidly acting anti-inflammatory medications,
including non-steroidal anti-inflammatory Drugs
(NSAIDs) and systemic and IA glucocorticoids.
 Disease Modifying Antirheumatic Drugs (DMARDs),
including nonbiologic (traditional small molecule or
synthetic) and biologic DMARDs, and an orally
administered small molecule kinase inhibitor, which
all have the potential to reduce or prevent joint
damage.
The non-biologic DMARDs most frequently used include
hydorxychloroquine, sulfasalazine, methotrexate, and
leflunomide [35, 36]. Biologic DMARDs, generally target
cytokines or their receptors, or are directed against other cell
surface molecules. These include anticytokine therapies, such
as the TNF-α inhibitors, etanercept, infliximab, adlimumab,
golimumab, and cetrolizumab pegol; the IL-1 receptor
antagonist, anakinra; and the IL-6 receptor antagonist,
toclizumab. They also include other biologic response
modifiers such as the T-cell co-stimulation blocker, abatacept,
which affects the Cytotoxic T Lymphocyte Antigen 4
(CTLA4-Ig), and the anti-Cluster of Differentiation 20 B
(CD20)-cell depleting monoclonal antibody drug, nituximab
[35, 36, 37, 38].
Several kinase inhibitors are in development for use in RA.
Tofactinib is in use in the USA and is under review for
approval in Europe. Tofacitinib is an orally administered small
molecule DMARD that inhibits cytokine and growth factor
signalling through interference with Janus kinases [35, 36].
Pharmacological Treatment of Osteoarthritis
According to the Osteoarthritis Research Society International
(OARSI) Treatment Guidelines Committee, there is no cure
for OA; treatment should manage symptoms, reducing pain
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[39, 40, 41]. Standard therapy is based on a combination of
pharmacological (e.g. paracetamol, NSAIDs, glucosamine)
and non-pharmacological methods (e.g. self-management and
education about exercise, diet, appropriate footwear) [4].
OARSI pharmacological intervention recommendations also
include three additional pharmacological interventions [4]:
 Topical use of NSAIDs and capsaicin as adjuncts or
alternatives to oral analgesic/anti-inflammatory
agents in knee OA.
 Treatment with glucosamine and/or chondroitin
sulphate in knee or hip OA.
 The use of weak opioids and narcotic analgesics for
refractory pain in patients with hip or knee OA, when
other pharmacological agents have been ineffective or
are contraindicated.
Paracetamol (acetaminophen) is an aniline analgesic, generally
the first-line treatment recommendation [42]. Guidelines
suggest that NSAIDs should be used with or without
concurrent paracetamol if symptom relief is not sufficient with
paracetamol alone [4, 43]. NSAIDs doses should be the
minimum for effective results, and long-term use avoided [4].
They may be only slightly better than placebo in providing
short-term pain relief [4], and are associated with important
side effects: Gastrointestinal bleeding, the most significant side
effect, causes approximately 16,500 and 2200 deaths, and
107,000 and 12,000 hospital admissions in the USA and
United Kingdom respectively, and is of particular concern in
older patients [44, 45].
Intra-articular (IA) corticosteroid injections can provide rapid
relief for up to four weeks [46]. IA hyaluronic acid injections
administered weekly for 3-5 weeks [47] have provided slower
onset but more prolonged (up to 12 weeks) relief than
corticosteroids [48, 49].
Glucosamine
Glucosamine was first used in the 1960’s as a topical
medication for OA pain in Germany [50, 51]. Subsequently, it
was developed as an oral preparation available on prescription
(Rx) in Europe [52, 53]. It is available in many countries
without prescription and is marketed to alleviate arthritic pain
of the knee, and as a prophylactic agent against joint damage
due to age or overuse [54]. Typically, glucosamine is
formulated as the N-acetyl, sulphate, or hydrochloride (HCL)
salt. In Australia glucosamine is usually formulated as a
sulphate or HCL salt and alone or combined with chondroitin
sulphate in capsules of 500 mg of glucosamine salt and 400
mg chondroitin sulphate, with a recommended daily dose of
three capsules per day [55].
Pharmacological Mechanism of Action of Glucosamine
Glucosamine as a Stimulant for the Synthesis of
Glycosaminoglycan
Glucosamine is preferentially incorporated by chondrocytes
into the components of glycosaminoglycan chains in cartilage
[56], stimulating synthesis of physiological proteoglycans [57,
58, 59] and decreasing the activity of catabolic enzymes in the
cartilage, including matrix metalloproteinases (MMPs) [60].
In vivo, it is effective in animal models of OA [61, 62].
Initially, the mechanism of action was considered simply as
above. However, this seems an oversimplification. While
metabolic effects exerted at the level of articular cartilage
might support a long-term joint structure-modifying activity,
they hardly explain the relatively short-term symptomatic
benefit outlined in clinical trials [63].
Recent studies demonstrate high glucosamine concentrations
stimulate glycosaminoglycan synthesis in vitro [64], and may
exceed the concentrations achieved in biological fluids after
oral administration to humans [65]. Nevertheless, in vitro
models also show it was effective in increasing proteoglycan
levels by up-regulating the expression of corresponding genes
at concentrations 100-fold lower and compatible with those
found in biological fluids during human treatment [57]. An
alternative hypothesis suggests the existence of glucosamine
metabolic activities in tissues where extracellular glucosamine
concentrations might be higher, including the intestine, liver
and kidney, such that it might modulate the compound’s anti-
arthritic effects [66]. Yet another alternative hypothesis
suggests that the increase in the production of cartilage
extracellular matrix is mediated by glucosamine-induced up-
regulation of Transforming Growth Factor-[beta](TGFb),
which has been observed at clinically relevant concentrations
in the low micromolar range [67].
Glucosamine as an Inhibitor of the Cytokine Pro-
Inflammatory Process
A unifying hypothesis for glucosamine sulphate’s mechanism
of action in OA was recently proposed. This refers to
glucosamine-induced reversal of the pro-inflammatory and
joint-degenerating effects of IL-1β [68, 69] through the
blockade of the cytokine intracellular signalling cascade, by
inhibiting the activation of the NFk-B pathway [70]. It inhibits
the IL-1 β-induced activation and nuclear translocation of
NFk-B in human osteoarthritic chondrocytes [71]. Further, it
inhibits both gene expression and protein synthesis of COX 2
selectively over COX 1, via the inhibition of NFk-B activation,
preventing the release of PGE 2 into the culture medium [70].
Several new lines of evidence are emerging to further
substantiate this mechanism. NFkB activity has been found to
be inhibited by glucosamine sulphate in both human
chondrocytes and synoviocytes, with subsequent decrease in
COX 2 protein synthesis, PGE 2 and NO release, showing a
pattern that differs from that of other potential
antiosteoarthritic agents and NSAIDs [72]. Moreover,
glucosamine sulphate consistently decreased IL-1 β-induced
MMP synthesis in both types of cell [71].
An in vitro study confirmed the suppressive effect of
glucosamine on both anabolic and catabolic gene expression in
the osteoarthritic cartilage [73]. The authors speculate that the
effect of glucosamine sulphate as a potential disease-
modifying agent might be due to anti-catabolic activities,
rather than anabolic activities. Interestingly, glucosamine
sulphate has been found to be a stronger inhibitor than the
hydrochloride [70]. This and other recent human
pharmacokinetic findings help to explain the different findings
of recent clinical trials between these two glucosamine salts.
Glucosamine as an Antioxidant
Glucosamine also has strong antioxidant and immuno-
stimulating properties [5, 6, 7, 8].  The general reduction
reaction equation for glucosamine, using N-Acetyl-D-
glucosamine as an example is as follows [73]:
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N-Acetyl-D-glucosamine + 02 → N-Acetyl-D-glucosaminate
+ H2O2
Recent research by Xing, Liu, Guo et al. (2006) [6]
investigating the antioxidant activity of glucosamine HCL in
vitro showed strong scavenging activity for superoxide/HO–
and pronounced reducing power. This was shown to increase
with increasing concentration, was quite linear and similar to
that of ascorbic acid (vitamin C). The reducing properties of
glucosamine HCL are associated with the presence of
reductones that have been shown to exert antioxidant action by
breaking the free-radical chain through donating a hydrogen
atom [6].
Studies of the antioxidant activity of glucosamine sulphate
produced similar results. The scavenging ability of
glucosamine sulphate was pronounced; increasing with
increasing concentration and its reducing power was also
strong. In addition glucosamine sulphate was shown to inhibit
radical mediated expression and activation of NFk-B proteins,
and enhance reduced GSH level in oxidatively stressed human
chondrocytes, thus improving cellular redox balance [5, 7].
Another study demonstrated that glucosamine exhibited strong
antioxidant ability in terms of its chelating effect on ions such
as the ferrous ion (Fe2+). This ability, removed ions from
substances such as deoxyribose, lipid and protein such that
they were protected from oxidative damage. In terms of
immuno-stimulating ability, D-glucosamine exerted a strong
effect on the phagocytosis of macrophages, indicating that pre-
treatment could augment the humeral and cellular immune
response [8].  This study presented the first evidence of
sulphated glucosamine being efficacious in attenuating
oxidation-related damage to cells via mechanisms involving
radical scavenging, and suggests a superior treatment efficacy
compared to non-sulphated glucosamine. Particularly, this
effect was observed in cells involved in OA, such as
chondrocytes and macrophages. From the results of this study,
both glucosamine and sulphated glucosamine act to prevent
oxidation of membrane lipids.
The ROS-mediated protein damage has been reported to be
higher in OA patients, thus the role of sulphated glucosamine
in protecting DNA from damage mediated through OH
produced from the concerted action of H2O2 and Fe2+ is highly
significant [8].  In addition, consistent with a role for oxidative
stress in pathogenesis of OA, clinical and preclinical studies
have correlated increases in markers of oxidative stress and
lower levels of the body’s natural antioxidants, such as GSH,
with disease severity [8]. GSH is up-regulated in the presence
of sulphated glucosamine, and this ability promotes its potency
against intracellular oxidative stress.
Aim
The aim of this study was, to explore consumer’s perception of
the efficacy and tolerance of glucosamine preparations in
inflammatory joint diseases.
METHOD
The first component was a qualitative observational survey. A
20-question survey was administered to members of the
community who self-selected to use glucosamine, recruited
through a poster campaign in local community pharmacies, to
capture their personal experience of the efficacy and toxicity.
Survey questions were based on validated clinical methods for
assessing pain and joint functional movement, using a visual
pain scale and visual joint-function scale [74, 75, 76, 77, 78,
79, 80, 81, 82, 83].
The survey data was found to be not normally distributed.
Non-parametric tests were used to test the statistical
significance of the results. The tests used were:
 The Shapiro Wilk test [84]
 The Wilcoxon signed-rank sum test [85]
 The Kruskal-Wallis test [86]
 The Bonferoni adjustment method [87]
RESULTS
Out of 87 participants (aged 40-84 years), 91.9% and 91.7%
stated that glucosamine reduced their pain and improved their
movement (Table 1).
Table 1 Reduction in joint pain versus time since started
glucosamine
Total Less than 6
months
6 months to a
year 1–2 years
More than 2
years
Total answering 86 13 24 16 10100% 100% 100% 100% 100%
Yes 79 7 24 16 1091.9% 53.8% 100% 100% 100%
No 7 6 - - -8.1% 46.2%
Pain was significantly reduced by 3-4 points (out of possible 5)
in 46.5% of participants.  Joint movement reported significant
improvement of 1-2 points out of a possible 5, in 51.7% of the
participants (Table 2).
Statistical analysis was performed to ascertain whether the
difference between pain scores and joint movement scores
before and after taking glucosamine was significant. Due to the
data being not normally distributed, the Wilcoxon signed-rank
sum test was used. For both joint pain and joint
movement/function, the score difference before compared to
after taking glucosamine was found to be statistically
significant with Prob>z = 0.00001. This suggests that after
taking glucosamine participants experienced a significant
reduction in pain and improvement in joint movement.
All of the participants who indicated that they had used
glucosamine for more than six months, reported pain reduction
and joint-movement improvement after using glucosamine
ranging from 1–2 points through to 5 or more points on the
rating scales. Six participants indicated that glucosamine was
not effective in reducing their pain and four participants
indicated that it did not improve their joints function. The
participants reporting negative results took glucosamine for
less than 6 months (Table 3).
Insert Table 3 here
Statistical testing was conducted to ascertain whether the
difference between pain scores and joint-movement scores in
participants taking glucosamine for more than six months
compared to those taking glucosamine for less than six months
was significant.
For joint pain, the score difference between taking
glucosamine for more than six months and taking glucosamine
for less than six months was significant, with Prob>z = 0.0018
(Wilcoxon signed-rank sum test).
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Table 3 Reduction in joint pain versus time since started
glucosamine
Total Less than6 months
6 months
to a year
1–2
years
More than
2 years
Total
answering
86 13 24 16 10
100% 100% 100% 100% 100%
Yes 79 7 24 16 1091.9% 53.8% 100% 100% 100%
No 7 6 - - -8.1% 46.2%
This suggests that taking glucosamine for longer than six
months results in significant reduction in overall pain.
For joint-movement improvement, the score difference
between taking glucosamine for more than six months and
taking glucosamine for less than six months was significant,
with Prob>z = 0.0343. Taking glucosamine for a period longer
than six months’ had a statistically significant improvement in
overall joint movement.
Most participants indicated that their arthritic pain was
associated with the knees, and most had been diagnosed with
OA. However, five of the participants had been diagnosed with
RA, and all of the RA participants reported significant
decreases in pain and improvement in joint movement ranging
from 1-2 points through to 5 points on the visual scale after
taking daily 1500mg of Sulphate for over 6 months.
There were no reports of glucosamine intolerance across the
sample (44 males and 43 females). Most participants started
taking glucosamine on the advice of their pharmacist (50%) or
their doctor (50%) to improve joints pain and function even if
they did not receive a medical diagnosis of arthritis.
DISCUSSION
Efficacy of Glucosamine
Studies relating to the efficacy of glucosamine have been
primarily concerned with glucosamine as a
supplementary/complementary treatment for OA rather than
RA, and have yielded mixed results. A number of meta-
analyses have been conducted on glucosamine, and have
shown that glucosamine may provide better pain relief and
improve function compared to placebo, while others have not
reported benefit [88, 89, 90, 91, 92, 93, 94, 95]. A possible
explanation for the mixed findings is a study reporting that
glucosamine sulphate consistently produced better
symptomatic benefits compared to glucosamine HCL [94].
This suggests that the form of glucosamine being used might
possibly influence results. Two studies involving either
paracetamol (acetaminophen) or NSAIDs as the comparator
have shown that glucosamine sulphate was at least equal to,
and in some studies superior to, NSAIDs in providing
symptomatic pain relief [96].
The critical analysis of a selected neutral/negative result study
reveals the following:
A study conducted in 1999 [97] concluded that there was no
significant difference between glucosamine and placebo in
terms of pain-score results. An analysis of the study reveals
that 118 patients with moderate pain for at least six months
due to primary knee OA and with radiological changes. The
patients were given 1500 mg daily of glucosamine HCL versus
placebo for eight weeks. Patients who had previously taken
glucosamine or those who had received an IA injection of
corticosteroids within the previous six months were excluded.
The negative results may be largely due to the experimental
design/methodology of the study. The current best-practice
guidelines based on meta-analyses conducted in 2006, 2008
and 2010 [88, 89, 95] recommend a dose of 1500 mg for a
period of six months for full benefits to be achieved.
Furthermore, these guidelines recommend the use of
glucosamine sulphate rather than the HCL version for better
results.
Critical analysis of a positive-result study [96] found that the
study concluded that administration of glucosamine to OA
patients resulted in significant improvement in terms of the
Lequesne index pain scores versus placebo. The study
consisted of 318 patients with moderate pain for at least three
months who were given 1500 mg daily of glucosamine
sulphate versus placebo for six months. Patients already taking
glucosamine were excluded from the study. These positive
results may be largely due to the experimental design aligning
with current best-practice recommendations pertaining to the
use of glucosamine in the treatment of OA [88, 89, 95].
Safety and Toxicity of Glucosamine
A 2008 review of 20 clinical trials reported no significant side
effects from the use of glucosamine [91]. This is consistent
with other evidence indicating that the long-term use of
glucosamine is associated with only minor and infrequent
adverse effects – primarily mild and temporary gastrointestinal
symptoms. It is believed that glucosamine does not carry risks
such as gastric bleeding or ulcers, and does not raise the risk of
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Total answering 86 44 42 22 23 20 21 33 36 17100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
No pain improve-ment 8 4 4 3 3 2 - 6 - 29.3% 9.1% 9.5% 13.6% 13.0% 10.0% 18.2% 11.8%
Pain improve-ment (1–2
points)
28 16 12 10 7 4 7 14 12 2
32.6% 36.4% 28.6% 45.5% 30.4% 20.0% 33.3% 42.4% 33.3% 11.8%
Pain improve-ment (3–4
points)
40 19 21 8 10 11 11 10 20 10
46.5% 43.2% 50.0% 36.4% 43.5% 55.0% 52.4% 30.3% 55.6% 58.8%
Pain improve-ment (5+ points) 10 5 5 1 3 3 3 3 4 311.6% 11.4% 11.9% 4.5% 13.0% 15.0% 14.3% 9.1% 11.1% 17.6%
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heart attack, stroke, or kidney disease, as do some first-line
pharmacological treatments [88].
However, one potential safety concern involves blood sugar
regulation. An initial study in a diabetic animal model raised
concerns that glucosamine supplementation might increase
insulin resistance [98, 99]. Subsequent studies conducted in
2006 and 2007 in patients with diabetes and OA found that
glucosamine did not directly affect blood-glucose levels or
cause worsening of insulin sensitivity. In addition, it had no
effect on levels of either high-density lipoprotein (HDL) or
apolipoprotein A1, a constituent of HDL 100, 101]. A recent
meta-analysis of clinical studies indicates that glucosamine
may decrease insulin sensitivity and increase fasting glucose.
The proposed mechanism is as follows: Glucosamine is
thought to be a competitive inhibitor of beta cell glucokinase.
Glucokinase in beta cells has a role in sensing glucose and
stimulating insulin secretion. Thus, glucosamine may raise the
glucose threshold for glucose stimulated insulin secretion and
lead to higher plasma fasting glucose levels as a result [102].
Until definitive information is available, blood sugar levels
should be closely monitored if glucosamine preparations are
given to diabetic and glucose-intolerant patients.
A further safety consideration is that, since most glucosamine
is prepared from shellfish, it should not be recommended to
patients with significant seafood allergy, although case reports
show that patients do not typically react to glucosamine [103].
A study conducted by Knudsen and Sokol (2008) [104]
discussed the possibility that glucosamine may result in a
potential interaction between warfarin (an anti-coagulant
medication) and glucosamine that is associated with an
increase in the International Normalised Ratio (INR). The
USA Food and Drug Administration (FDA) MedWatch
database identified 20 reports of glucosamine or glucosamine-
chondroitin sulphate use with warfarin associated with altered
coagulation (manifested by increased INR, or increased
bleeding or bruising). The study further states that the World
Health Organisation (WHO) adverse drug reactions database
documented 21 spontaneous reports of increased INR
associated with glucosamine use, 17 of which resolved when
glucosamine was stopped. The study concludes, however, that
the mechanism is not understood, and that more research is
required to identify the mechanism.
Despite the above it is assessed that it is unlikely that
glucosamine will have adverse interactions with other drugs
since glucosamine is mainly absorbed via glucose transporters
and does not compete for general absorption mechanisms. In
addition, it is mainly metabolised independently of the
cytochrome P450 enzyme system [105].
Significance of Results
The results of the study indicate that glucosamine is effective
in the treatment of OA. A majority (91.9%) of respondents
equally distributed between male and female, stated
glucosamine had helped reduce pain in their joints. Only 8.1%
stated glucosamine had been ineffective. Further, 91.7% of
respondents stated that taking glucosamine had improved the
movement in their joints. Likewise, 93.2% of respondents
indicated that taking glucosamine has helped to improve the
function of their joints due to the pain reduction.
It is clear from the study that those patients who used
glucosamine for more than six months perceived a significant
reduction in pain and an improvement in joint movement. The
results show that all respondents (100%) reported that
glucosamine was beneficial in reducing their joint pain and
improving their joint-movement after using glucosamine
ranging from 1–2 points through to 5 or more points on the
rating scales.
However, amongst those respondents who took glucosamine
for less than six months, nearly half reported no benefit from
taking glucosamine. This leads to the conclusion that for
glucosamine to be effective in reducing joint pain, it must be
taken for a period exceeding six months. This is supported by
the existing literature. The current best-practice guidelines
recommend a glucosamine dose of 1500 mg daily for a period
of six months for full benefits to be achieved. The guidelines
further recommend the use of glucosamine sulphate rather than
the HCL formulation [88, 90, 95, 106]. A recent meta-analysis
conducted in 2013 agrees with this assessment, concluding that
whilst glucosamine HCL was ineffective for pain reduction in
patients with knee OA, glucosamine sulphate was effective
when administered for more than six months [107].  A small
number of the total number of participants in the study
indicated that glucosamine had not been effective. All of these
participants took glucosamine for less than six months,
corroborating the supporting literature.
The literature review in this study provided insight on the
possible benefits of glucosamine in relieving oxidative stress
associated with arthritis. A small group of participants reported
that they were diagnosed with RA (five out of 87 participants),
and 100% of those participants reported a highly significant
decrease in pain ranging from 1–2 points through to 5 points or
more on the visual scale. They also reported a significant
improvement in joint function/movement ranging from 1–2
points through to 5 or more points. All of the participants with
a self-reported RA diagnosis indicated they had been taking
glucosamine for longer than six months at the recommended
dose of 1500mg per day. Given the role of ROS and the
resultant oxidative stress found in both the pathogenesis and
disease progression of RA, and the reported antioxidant
activity of glucosamine, inferences can be made regarding the
findings of this study which may be rationalised as follows:
That is, the antioxidant properties of glucosamine may be
directly responsible for the positive effects of glucosamine
reported by RA suffers who took part in this study.
A critical literature review revealed that few studies have
investigated the effectiveness of glucosamine in other types of
arthritis and to date; no research has been conducted regarding
the antioxidant/pro-oxidant activity of glucosamine in human
patients suffering from IJDs. Particularly, there has also been
very little research conducted on the efficacy of glucosamine
in the treatment of RA patients. Nakamura et al. (2007) [108]
found that glucosamine treatment produced noticeable
improvements in symptoms of RA patients. However,
antioxidant status was not measured in this study.
Limitations
This study is based solely upon patient perceptions not any
formal investigations. Nevertheless the reported benefits
appear strong and it is unlikely that the results were purely
placebo.
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CONCLUSION
The results of this study indicated that health professionals
have a degree of confidence in the benefits of glucosamine as a
complementary treatment of Osteoarthritis. However further
study is required regarding efficacy.
In further examining the antioxidant effect of glucosamine, a
further research question arises regarding what possible role
glucosamine may have in the treatment of other diseases
associated with oxidative stress. The existing literature reports
antioxidant properties of glucosamine. Further research
examining the possible role of glucosamine in the treatment of
other diseases associated with oxidative stress is surely
warranted.
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